Nuo Therapeutics Reports 153% Revenue Growth to $1.77 Million in Latest Quarter

Nuo Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenues of approximately $1.77 million for the three months ended June 30, 2026, a substantial increase of 153% compared to $700,202 in the same period last year. For the six months ending June 30, 2026, total revenues reached approximately $3.07 million, up 159% from $1.18 million in the prior year. The increase in revenue was primarily driven by higher product sales, particularly from the Aurix product line and distribution fee revenue from a partnership with Smith+Nephew.

Despite the revenue growth, Nuo Therapeutics reported a net loss of $277,601 for the three months ended June 30, 2026, a decrease from a loss of $649,689 in the same period of 2025. For the six-month period, the net loss was approximately $896,067, compared to a loss of $1.40 million in the prior year. The company’s gross profit for the three months was approximately $1.17 million, yielding a gross margin of 66%, down from 77% in the previous year, attributed to lower margins on certain product sales to Smith+Nephew.

Operationally, Nuo Therapeutics has made strides in expanding its customer base, establishing contractual relationships with over 200 third-party entities and individual representatives as of June 30, 2026. The company has also seen an increase in its employee headcount, reflecting its efforts to bolster its commercial operations following the restart of business activities in October 2021. The partnership with Smith+Nephew, which includes a distribution agreement for a private label of the Aurix product, has been a key strategic development, contributing to the revenue growth and enhancing market presence.

The company’s balance sheet as of June 30, 2026, showed total assets of approximately $2.63 million, up from $1.85 million at the end of 2025. However, total liabilities increased significantly to $4.16 million, compared to $2.80 million at the end of the previous fiscal year, primarily due to the issuance of secured promissory notes. Nuo Therapeutics reported an accumulated deficit of approximately $35.7 million, raising concerns about its ability to continue as a going concern without additional capital. The company indicated that it may need to secure further financing to support its operations and growth initiatives.

Looking ahead, Nuo Therapeutics remains focused on expanding its market share in the chronic wound care sector, leveraging its innovative Aurix product. The company anticipates continued revenue growth driven by increased product adoption and strategic partnerships. However, it also acknowledges the challenges posed by its current financial position and the need for additional funding to sustain operations and achieve profitability.